Articles On Neuren Pharmaceuticals (ASX:NEU)

Neurotech’s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company’s NTI164 compares favourably to DAYBUE, the only FDA-approved...

Share tips and stock recommendations for the Australian (ASX) share market – buy, hold, and sell. Michael Gable is an expert guest commentator for the stock market newsletter thebull.com.au. This post is an extract from the newsletter dated...

Turning $100,000 into a million bucks might sound like magic. But no one needs supernatural powers if they use ASX shares and compounding to their advantage. Allow me to introduce you to three stocks that I reckon could do the trick: Tempo...

If you've been a bunny and missed out on the 3.45% gains already delivered by the S&P/ASX 200 Index (ASX: XJO) so far in 2024, fear not! Because, right now is an egg-cellent time to treat yourself to some sweet new investments. But rem...

When an S&P/ASX 200 Index (ASX: XJO) stock outperforms all and sundry one year but then suddenly dips, you need to at least check out what's happening. Neuren Pharmaceuticals Ltd (ASX: NEU) was the highest climber in the ASX 200 last y...

The green graphics card giant is making a motza. But did you know some ASX companies have even bigger profit margins than Nvidia Corp (NASDAQ: NVDA)? Masterfully riding the AI wave, Nvidia looks like the Kelly Slater of computer hardware....

Many Australians have the impression that investing in stocks is only for rich people.  But that cannot be further from the truth. If you have just $500 you could make a pretty useful start to a portfolio. I have taken the liberty of picki...

It's been a horror end to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Friday. The ASX 200 fell sharply at market open, dropping as muc...

Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study   Dimerix...

The S&P/ASX 200 Index (ASX: XJO) endured another wild day of trading this Tuesday. Despite an initially strong rise this morning, investors spent most of...

If you have $10,000 to invest right now, there are some excellent S&P/ASX 200 Index (ASX: XJO) stocks that can grow that money. When choosing stocks, I take the view of whether that cash will be invested in companies that will be doing...

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter who others have debunked. By Tim Boreham ASX Code: ((NEU)) Share price: $20.16 Shares on issue: 127,234,676 Market cap: $2.56 billion Chief ex...

The Insurance Australia Group Ltd (ASX: IAG) interim dividend announced last month was 67% higher than last year, at 10 cents per share. That's some very nice turbocharged passive income, right there. And analysts say it's only going to...

Nyrada jumped 400pc in a single day last month The company reported good results from its Brain Injury Program Could Nyrada be the next Neuren?   Nyrada’s 400% share price rally on February 28 was the biggest single day jump of any ASX st...

The S&P/ASX 200 Index (ASX: XJO) might have risen four months straight, but many experts are still bullish about the rest of 2024. Shaw and Partners portfolio manager James Gerrish said in his newsletter that his team is "bullish equit...

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AUA)) - Audeara ((CMW)) - Cromwell Property ((360)) - Life360 ((NEU)) - Neuren Pharmaceuticals ((RDG)) - Resource Development Check it out at ...

With earnings season nearing an end, we showcase 12 ASX shares that delivered some of the best profit boosts this season. In some cases, these mega profit gains led to significantly increased dividends for ASX investors, too. Which ASX s...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price gained 1.1% to close at $19.36 on Thursday despite encountering some turbulence in late afternoon trading. Most of the gains occurred at the beginning of today's session with the stoc...

Neuren Pharmaceuticals (ASX:NEU) has reported highlights from the fourth quarter 2023 earnings announcement and its partner Acadia Pharmaceuticals' conference call.

The ASX200 closed flat despite futures having tipped a moderate green day on market as investors endeavoured to digest the Australian CPI report.  Core inflation has declined by 0.1 per cent from 4.2 to 4.1 per cent – and while that’s he...

Lithium miners surge NextDC also jumps on strong H1, but Flight Centre tumbles Aussie inflation lowest in two years   The ASX 200 closed modestly lower on Wednesday with, with gains in Tech offset by losses in Comm Services and Staples se...

The ASX200 has been trading quite flat. The IT sector has surged, up more than 2 per cent, while telecommunications is struggling, shedding about a per cent. The Australian Bureau of Statistics (ABS) reported a 3.4 per cent rise in in...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down 0.1% to 7,654.3 points. Four ASX shares that are falling more than most today are listed...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are crashing deep into the red today. At one stage today, the ASX 200 pharmaceuticals stock was down 15% to $18.16. Neuren's shares have recovered a touch since then but remain down by 12%. Why...

  Neuren’s Daybue sales meet target Proteomics granted patent in Europe Nyrada’s brain injury drug shows efficacy in animal testing   Neuren’s Daybue sales meet target, crushing short seller’s claims Neuren Pharma (ASX:NEU) says Q4 2023 s...

Neuren has reported over US$87M in sales of DAYBUE in Q4 of 2023 The drug is sold by NASDAQ-listed Acadia in the US to treat a condition called Retts Earlier this month, short sellers claimed Acadia was lying to the market about the...

One in eight people in the world have some form of mental disorder TrivarX’s AI technology diagnoses mental health via sleep monitoring Stockhead reached out to TrivarX’s COO, Kai Sun   Mental health has always been a big global issue, bu...

If you want to receive the next Insurance Australia Group Ltd (ASX: IAG) dividend, then you will have to act fast. That's because the insurance giant's shares are going ex-dividend on Wednesday. When a share trades ex-dividend, it means th...

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

It turned out to be a shaky, but still positive, start to the trading week for the S&P/ASX 200 Index (ASX: XJO) and most shares this Monday. By the close of trading tod...

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

By Greg Peel Resourceful The ASX200 shot up 76 points from the open on Friday on a combination of renewed positive sentiment over the week and a 0.5% gain on Wall Street. It then dipped and finally steadied through the afternoon to close up...

On Friday, the S&P/ASX 200 Index (ASX: XJO) ended the week with a solid gain. The benchmark index rose 0.7% to 7,658.3 points. Will the market be able to build on this on Monday? Here are five things to watch: ASX 200 expected to edge...

It's funny to call an ASX stock that's rocketed 217% in the past year a "bargain". But that's precisely the situation we have with Neuren Pharmaceuticals Ltd (ASX: NEU), according to the experts at Blackwattle. Let's check out their ration...

ASX adds 0.7pc to close out the week in a positive frame of mind IT and materials rise, thanks to a softening US dollar and general commodity weirdness Small caps led by NKOTB, Australian Wealth Advisors Group on a solid debut   Materi...

ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel...

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX sh...

We had a team meeting this morning. We were discussing how to make sure our readers and members were best equipped to use our advice. Spoiler: some of the people who get grumpy with our advice are those who, ahem, don't actually follow it....

Neuren Pharmaceuticals (ASX:NEU) shares are tanking on news its US partner allegedly mischaracterised the safety of a drug for children The findings come from a short-selling firm That firm, Culper Research, reports the drug hospital...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are ending the week deep in the red. The ASX 200 healthcare share was down 13% to $20.04 before being paused from trade. What's going on with this ASX 200 healthcare share? Investors have been h...

The S&P/ASX 200 Index (ASX: XJO) has just given ASX investors a not-so-merry start to December today, closing the trading week with a mild loss....

The S&P/ASX 200 Index (ASX: XJO) was on form in November and charged higher. Over the period, the benchmark index rose 4.5% to finish the period at 7,087.3 points. While most ASX 200 shares climbed with the market, some stood out wit...

ASX health stocks flat in past five days in line with broader markets  Avita lowers full year 2023 guidance after slower progress in its customer’s VAC processes EBOS decides against acquisition of animal care business, reportedly Greencro...

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are having a positive start to the week. In afternoon trade, the ASX 200 pharmaceutical stock is up almost 2% to $14.93. Why is this ASX 200 stock rising? The catalyst for the rise in Neuren's s...

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a subdued note. The benchmark index fell 0.1% to 7,049.4 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 200 expe...

ASX health stocks rise in past five days and outpace broader markets for second week All study visits complete in Neuren’s Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid Syndrome Ramsay Health Care after revealing that it has reach...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...